NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients |
|
|
| Active, not recruiting | 3 | 702 | Europe | Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin | Prof. Dr. med. Claus Rödel | Rectal Cancer Stage III | 09/23 | 09/28 | | |
PRESTO, NCT05713838: Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery |
|
|
| Recruiting | 2 | 32 | Europe | Durvalumab, IMFINZI, FLOT, mFOLFOX-6, Radiotherapy | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Esophagus Adenocarcinoma | 12/25 | 12/28 | | |
REALTRK, NCT04557813: Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion |
|
|
| Active, not recruiting | N/A | 88 | Europe | | iOMEDICO AG, Roche Pharma AG | NTRK Family Gene Mutation | 10/26 | 10/26 | | |
